Finding into death of YIL
Deceased
YIL
Demographics
54y, female
Date of death
2025-02-07
Finding date
2025-12-11
Cause of death
Complications of metastatic cholangiocarcinoma
AI-generated summary
YIL was a 54-year-old woman with Down syndrome who died from complications of metastatic cholangiocarcinoma. She had been appropriately transitioned to palliative care in 2024 after her cancer progressed despite chemotherapy and surgery. In her final weeks, she experienced increasing fatigue, confusion, seizures, and mobility decline. She was admitted to Austin Hospital's palliative care unit on 5 February 2025 for comfort-focused care and died peacefully on 7 February 2025 following a seizure, with family present. The care pathway was appropriate for her condition, with timely transition to palliative management and seizure management with midazolam. No clinical errors or preventable factors were identified in her management.
AI-generated summary and tagging — may contain inaccuracies; refer to original finding for legal purposes.
Specialties
Drugs involved
Contributing factors
- metastatic cholangiocarcinoma progression despite initial surgery and chemotherapy
- seizure activity in the terminal phase
Full text
Related cases
Source and disclaimer
This page reproduces or summarises information from publicly available findings published by Australian coroners' courts. Coronial is an independent educational resource and is not affiliated with, endorsed by, or acting on behalf of any coronial court or government body.
Content may be incomplete, reformatted, or summarised. All court orders for redaction and non-publication are respected; documents with technically defective redaction have been excluded from the database entirely. Always refer to the original court publication for the authoritative record.
Copyright in original materials remains with the relevant government jurisdiction. AI-generated summaries and tagging are for educational purposes only, may contain inaccuracies, and must not be treated as legal documents. We welcome feedback for correction —